Amoxicillin and zoloft

Comments: I was being treated

for

I’m sure its the penicillin, and a search finds that I may have developed an allergy to penicillia. Im relieved to find this out as I thought something else was wrong, just a reaction to the medication. I have a drug allergy that no one could identify because the symptoms don’t appear until 24 hrs.

I believe it is not the drug but the carrier, and I believe the drug manufacturer is aware of it.

I believe others that suffer from lipedemia are also allergic to this drug but the doctors are unaware of it so it goes undiagnosed. I believe many young people have also been put through unnecessary anguish because of this drug. There needs to be a full study of what I’m going to disclose.

I have done my homework, 119 IQ, sold the top gastroenterologist at U of M med center on my findings, but come up against the FDA and the medical insurance companies.

The drug company is Astra Zeneca, the drug is Propofol or Diprivan. Here is the kicker, it doesn’t show itself for 24 hrs. When you go back to the hospital it is finally diagnosed as idiopathic pancreatitis and never gets linked back to the drug you were administered 24 hrs. The Doctors love it, the hospitals love it, the insurance companies adore it, and for most it is a great drug.

For the few of us that aren’t so lucky because of our metabolism, or the very young who can’t speak for themselves, well too bad. I’m curious, is there is soy allergies, and what happens to those people?

It’s disclosed on the sheet way at the end of the disclosure which no Doctors are even aware of.

Astra Zeneca quickly pulled two other drugs out of trials because they caused pancreatitis immediately, hmmm, they were also immulsilfied in soy oil.

I wish someone would do an investigation for God’s sake. It wasn’t until we believed young people were dying that we spoke out. Get weekly health information and advice from the experts at Harvard Medical School.

home drugs a-z list side effects drug center augmentin xr (amoxicillin clavulanic potassium) drug.

AUGMENTIN XR® (amoxicillin and clavulanate potassium) DESCRIPTION. AUGMENTIN XR (amoxicillin and clavulanate potassium) extended release tablet for oral use is an antibacterial combination consisting of the semisynthetic antibacterial amoxicillin (present as amoxicillin trihydrate and amoxicillin sodium) and the ?-lactamase inhibitor clavulanate potassium (the potassium salt of clavulanic acid). Amoxicillin is an analog of ampicillin, derived from the basic penicillin nucleus 6-aminopenicillanic acid. The amoxicillin trihydrate molecular formula is C 16 H 19 N 3 O 5 S•3H 2 O, and the molecular weight is 419.45.

Chemically, amoxicillin trihydrate is (2S,5R,6R)-6-[(R)-(-)-2-Amino-2-(p-hydroxyphenyl)acetamido]-3,3dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid trihydrate and may be represented structurally as: The amoxicillin sodium molecular formula is C 16 H 18 N 3 NaO 5 S, and the molecular weight is 387.39.

Chemically, amoxicillin sodium is [2 -[2?,5?,6?(S*)]]-6-[[Amino(4hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2carboxylic acid monosodium salt and may be represented structurally as: Clavulanic acid is produced by the fermentation of Streptomyces clavuligerus .

It is a ?lactam structurally related to the penicillins and possesses the ability to inactivate a wide variety of ?-lactamases by blocking the active sites of these enzymes.

Clavulanic acid is particularly active against the clinically important plasmid-mediated ?-lactamases frequently responsible for transferred drug resistance to penicillins and cephalosporins.

The clavulanate potassium molecular formula is C 8 H 8 KNO 5 , and the molecular weight is 237.25.

Chemically, clavulanate potassium is potassium (Z)-(2R,5R)-3-(2-hydroxy ethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]-heptane-2-carboxylate, and may be represented structurally as: Inactive Ingredients.

Citric acid, colloidal silicon dioxide, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, sodium starch glycolate, titanium dioxide, and xanthan gum. Each tablet of AUGMENTIN XR contains approximately 13 mg of potassium and 30 mg of sodium. To reduce the development of drug-resistant bacteria and maintain the effectiveness of AUGMENTIN XR and other antibacterial drugs, AUGMENTIN XR should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria.

When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

AUGMENTIN XR Extended Release Tablets are indicated for the treatment of patients with community-acquired pneumonia or acute bacterial sinusitis due to confirmed, or suspected ?-lactamase–producing pathogens (i.e., H. pneumoniae with reduced susceptibility to penicillin (i.e., penicillin MICs = 2 mcg/mL). AUGMENTIN XR is not indicated for the treatment of infections due to S.

Data are limited with regard to infections due to S.

pneumoniae with penicillin MICs ? 4 mcg/ml [see Clinical Studies ]. In patients with community-acquired pneumonia in whom penicillin-resistant S.

pneumoniae is suspected, bacteriological studies should be performed to determine the causative organisms and their susceptibility when AUGMENTIN XR is prescribed.

Acute bacterial sinusitis or community-acquired pneumonia due to a penicillin-susceptible strain of S.

pneumoniae plus a ?-lactamase–producing pathogen can be treated with another AUGMENTIN® (amoxicillin/clavulanate potassium) product containing lower daily doses of amoxicillin (i.e., 500 mg every 8 hours or 875 mg every 12 hours). Acute bacterial sinusitis or community-acquired pneumonia due to S. AUGMENTIN XR should be taken at the start of a meal to enhance the absorption of amoxicillin and to minimize the potential for gastrointestinal intolerance. AUGMENTIN XR is not recommended to be taken with a high-fat meal, because clavulanate absorption is decreased.

The recommended dose of AUGMENTIN XR is 4,000 mg/250 mg daily according to the following table: Indication Dose Duration Acute bacterial sinusitis 2 tablets q12h 10 days Community-acquired pneumonia 2 tablets q12h 7-10 days.

Tablets of AUGMENTIN (250 mg or 500 mg) CANNOT be used to provide the same dosages as AUGMENTIN XR Extended Release Tablets.

This is because AUGMENTIN XR contains 62.5 mg of clavulanic acid, while the AUGMENTIN 250-mg and 500-mg tablets each contain 125 mg of clavulanic acid. In addition, the Extended Release Tablet provides an extended time course of plasma amoxicillin concentrations compared to immediate-release Tablets.

Thus, two AUGMENTIN 500-mg tablets are not equivalent to one AUGMENTIN XR tablet.

Scored AUGMENTIN XR Extended Release Tablets are available for adult patients who have difficulty swallowing. The scored tablet is not intended to reduce the dosage of medication taken; as stated in the table above, the recommended dose of AUGMENTIN XR is two tablets twice a day (every 12 hours).

The pharmacokinetics of AUGMENTIN XR have not been studied in patients with renal impairment.

AUGMENTIN XR is contraindicated in patients with a creatinine clearance of. The following are discussed in more detail in other sections of the labeling: Anaphylactic reactions [see WARNINGS AND PRECAUTIONS ] Hepatic Dysfunction [see WARNINGS AND PRECAUTIONS ] CDAD [see WARNINGS AND PRECAUTIONS ] Clinical Trials Experience. Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

In clinical trials, 5,643 patients have been treated with AUGMENTIN XR.

The most frequently reported

adverse

AUGMENTIN XR had a higher rate of diarrhea which required corrective therapy (4% versus 3% for AUGMENTIN XR and all comparators, respectively).

Two percent of patients discontinued therapy because of drug-related adverse reactions. In addition to adverse reactions reported from clinical trials, the following have been identified during postmarketing use of AUGMENTIN products, including AUGMENTIN XR. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. These events have been chosen for inclusion due to a combination of their seriousness, frequency of reporting, or potential causal connection to AUGMENTIN.

Gastrointestinal: Diarrhea, nausea, vomiting, indigestion, gastritis, stomatitis, glossitis, black “hairy” tongue, mucocutaneous candidiasis, enterocolitis, and hemorrhagic/pseudo membranous colitis.

Onset of pseudomembranous colitis symptoms may occur during or after antibiotic treatment.

Hypersensitivity Reactions: Skin rashes, pruritus, urticaria, angioedema, serum sickness-like reactions (urticaria or skin rash accompanied by arthritis, arthralgia, myalgia, and frequently fever), erythema multiforme, Stevens-Johnson syndrome, acute generalized exanthematous pustulosis, hypersensitivity vasculitis, and an occasional case of exfoliative dermatitis (including toxic epidermal necrolysis) have been reported [see WARNINGS AND PRECAUTIONS ].

Liver: A moderate rise in AST (SGOT) and/or ALT (SGPT) has been noted in patients treated with ampicillin-class antibiotics, but the significance of these findings is unknown.

Hepatic dysfunction, including hepatitis and cholestatic jaundice, [see CONTRAINDICATIONS ], increases in serum transaminases (AST and/or ALT), serum bilirubin, and/or alkaline phosphatase, has been reported with AUGMENTIN or AUGMENTIN XR. It has been reported more commonly in the elderly, in males, or in patients on prolonged treatment. The

histologic

Deaths have been reported [see CONTRAINDICATIONS , WARNINGS AND PRECAUTIONS ].

Renal: Interstitial nephritis, hematuria, and crystalluria have been reported [see OVERDOSAGE ]. Hemic and Lymphatic Systems: Anemia, including hemolytic anemia, thrombocytopenia, thrombocytopenic purpura, eosinophilia, leukopenia, and agranulocytosis have been reported during therapy with penicillins.

These reactions are usually reversible on discontinuation of therapy and are believed to be hypersensitivity phenomena.

There have been reports of increased prothrombin time in patients receiving AUGMENTIN and anticoagulant therapy concomitantly.

Central Nervous System: Agitation, anxiety, behavioral changes, confusion, convulsions, dizziness, headache, insomnia, and reversible hyperactivity have been reported rarely. Miscellaneous: Tooth discoloration (brown, yellow, or gray staining) has been reported.

Discoloration was reduced or eliminated with brushing or dental cleaning in most cases.

Probenecid decreases the renal tubular secretion of amoxicillin. Concurrent use with AUGMENTIN XR may result in increased and prolonged blood levels of amoxicillin. Abnormal prolongation of prothrombin time (increased international normalized ratio [INR]) has been reported in patients receiving amoxicillin and oral anticoagulants.

Appropriate monitoring should be undertaken when anticoagulants are prescribed concurrently. Adjustments in the dose of oral anticoagulants may be necessary to maintain the desired level of anticoagulation.

The concurrent administration of allopurinol and amoxicillin substantially increases the incidence of rashes in patients receiving both drugs as compared to patients receiving amoxicillin alone. It is not known whether this potentiation of amoxicillin rashes is due to allopurinol or the hyperuricemia present in these patients.

In controlled clinical trials of AUGMENTIN XR, 25 patients received concomitant allopurinol and AUGMENTIN XR.

However, this sample size is too small to allow for any conclusions to be drawn regarding the risk of rashes with concomitant AUGMENTIN XR and allopurinol use. AUGMENTIN XR may affect intestinal flora, leading to lower estrogen reabsorption and reduced efficacy of combined oral estrogen/progesterone contraceptives. High urine concentrations of amoxicillin may result in false-positive reactions when testing for the presence of glucose in urine using CLINITEST®, Benedict's Solution, or Fehling's Solution. Since this effect may also occur with AUGMENTIN, it is recommended that glucose tests based on enzymatic glucose oxidase reactions be used.

Following administration of amoxicillin to pregnant women, a transient decrease in plasma concentration of total conjugated estriol, estriol-glucuronide, conjugated estrone, and estradiol has been noted.

Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving AUGMENTIN XR.

These reactions are more likely to occur in individuals with a history of penicillin hypersensitivity and/or a history of sensitivity to multiple allergens. Before initiating therapy with AUGMENTIN XR, careful inquiry should be made regarding previous hypersensitivity reactions to penicillins, cephalosporins, or other allergens. If an allergic reaction occurs, AUGMENTIN XR should be discontinued and appropriate therapy instituted. AUGMENTIN XR should be used with caution in patients with evidence of hepatic dysfunction. Hepatic toxicity associated with the use of amoxicillin/clavulanate potassium is usually reversible.

Deaths have been reported (fewer than 1 death reported per estimated 4 million prescriptions worldwide). These have generally been cases associated with serious underlying diseases or concomitant medications [see CONTRAINDICATIONS and ADVERSE REACTIONS ]. Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including

AUGMENTIN

difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use.

Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.

If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile , and surgical evaluation should be instituted as clinically indicated. A high percentage of patients with mononucleosis who receive amoxicillin develop an erythematous skin rash.